leisure time -WSS

leisure time

author：hotspot 2025-08-26 23:44:49 - browse：466

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

hotspot

WSS

Free medical tuition alone isn't enough to close gaps in primary care

Galapagos to make CAR

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Illumina slashes 2023 revenue projections yet again

WuXi Biologics execs register to lobby as Congress comes for the company

Supreme Court to hear if Covid misinformation is protected speech

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Bright Health sells Medicare Advantage business to Molina

Dozens dead from Maui wildfires: What we know about the victims

Moonlake's readout produced a cash windfall. Risks remain

Montana youths win climate lawsuit against state for promoting fossil fuels

The cancer drug shortage isn’t new — and neither are the solutions

Supreme Court to hear if Covid misinformation is protected speech

Activists slam private health insurers over coverage restrictions

STAT series 'Denied by AI' wins major journalism prizes

Hollywood unions extend contract negotiations for actors

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

focus

Idaho college killings prosecutors challenge defense's grand jury claims

Health AI: on the border between health care and tech

STAT series 'Denied by AI' wins major journalism prizes

Boston hospital trains restaurant workers on naloxone for overdoses

Hospitals are dialing back on venture capital investing

Idaho college killings prosecutors challenge defense's grand jury claims

entertainment

Wikipedia

hotspot

explore